• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

14.49 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024
July 30, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
June 04, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts ↗
May 14, 2024
 
Via Benzinga
News headline image
The Analyst Landscape: 4 Takes On Amicus Therapeutics ↗
December 19, 2023
 
Via Benzinga
News headline image
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today. ↗
May 14, 2024
 
Via Benzinga
News headline image
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗
May 09, 2024
FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
May 09, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
May 08, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
May 01, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
March 20, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Stock Sees RS Rating Improve To 74 ↗
March 05, 2024
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
Via Investor's Business Daily
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
March 01, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
February 28, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
February 15, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Stock Sees Improved Relative Strength Rating ↗
February 09, 2024
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. 
Via Investor's Business Daily
News headline image
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
February 08, 2024
- Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease - 
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
February 01, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Time to buy these 3 healthcare companies that raised revenue guidance?
January 16, 2024
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance. 
Via MarketBeat
News headline image
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
January 07, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
December 05, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps ↗
November 15, 2023
These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on. 
Via InvestorPlace
Topics Bankruptcy
News headline image
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
November 08, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
November 01, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
October 27, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
October 03, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
October 02, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session ↗
September 29, 2023
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease ↗
September 28, 2023
The FDA has approved Amicus Therapeutics' (NASDAQ: FOLD) Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap